# Everolimus for Children With NF1 Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas

> **NCT01158651** · PHASE2 · COMPLETED · sponsor: **University of Alabama at Birmingham** · enrollment: 23 (actual)

## Conditions studied

- Glioma

## Interventions

- **DRUG:** RAD001 (Everolimus)

## Key facts

- **NCT ID:** NCT01158651
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07-10
- **Primary completion:** 2014-09-04
- **Final completion:** 2017-10-26
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2020-02-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01158651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01158651, "Everolimus for Children With NF1 Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01158651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*